An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DermTech (NASDAQ: DMTK) recently participated in the Outsourcing in Clinical Trials Southern California event, emphasizing the shift towards decentralized clinical trials to improve patient satisfaction and data quality. Senior Project Manager, Elisa Lanni, highlighted the challenges in patient recruitment and the necessity of adopting hybrid models in clinical research. DermTech's innovative Smart Sticker™ technology was showcased as a means to facilitate non-invasive skin sample collection, enhancing the overall patient experience in clinical studies.
Positive
Participation in a key industry event indicates strategic engagement and visibility.
Emphasis on decentralized clinical trials aligns with contemporary healthcare trends, potentially improving patient experiences and data quality.
Innovative technology (Smart Sticker™) may enhance non-invasive testing, appealing to a broader patient demographic.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Diego. The 9th annual event featured industry-leading speakers from the global clinical trial space.
Elisa Lanni, M.S., DermTech Stratum senior project manager, discussed the current challenges of patient recruitment and retention in clinical trials and how hybridization and decentralization can bridge the gap to create a better patient experience. The presentation, titled “Technological Advances in Clinical Trials – Exploring the Value of Decentralization,” emphasized how the traditional approach to clinical trials can be inconvenient and inaccessible for patients, leading to lesser quality data.
A potential solution enabled by DermTech Stratum reevaluates clinical trial design to consider the post-pandemic climate and how virtual or hybrid models have become the norm across work and healthcare settings. She elaborated on the benefits, risks and outcomes of using technology to decentralize clinical trials, which ultimately leads to greater patient satisfaction, a more diverse patient population, better retention and cost savings. Finally, she expanded on the role of DermTech Stratum, DermTech’s translational medicine service offering, in clinical trials. By leveraging DermTech’s innovative Smart Sticker™, DermTech Stratum enables remote and non-invasive skin sample collection. A recording of Lanni’s full presentation is available here.
“We are honored to have been a part of Outsourcing in Clinical Trials Southern California to share our perspective on the new wave of decentralization in clinical trials and how this will ultimately improve the patient experience,” said Lanni. “Without patients, we have no data. We must put innovative technology at the forefront of our approach to dermatological research and development.”
Lanni is a highly experienced project manager with a specialization in clinical operations and logistics. She has spent more than 10 years managing industry-sponsored clinical trials in biotech, contract research organization (CRO) and academic settings.
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” "outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency, implications and interpretations of any study results, expectations regarding reimbursement or cash collection patterns from Medicare from commercial payors and related billing practices or number of covered lives, and DermTech’s ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and commercial payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
